MEB-ZIN Parallel Procedure: Optimizing Market Access in the Netherlands

Published on January 19, 2023

*/ /*-->*/ /*-->*/ /*-->*/ /*-->*/ /*-->*/

In this brief we explore the introduction and implications of the MEB-ZIN Parallel Procedure pilot, which was launched in 2019 in the Netherlands. Experts Eline Middelburg, Cédric Driessen, Alexander Vos, and Anke Ritte cover the rationale for its creation, as well as an overview of products that have gone through the process so far.

First results of the MEB-ZIN Parallel Procedure pilot showcases acceleration of patient access through enhanced collaboration

On average, the period between EU market approval and patient access in the Netherlands can span several months, which can be detrimental to patient access to potentially life-saving medicines.

In an attempt to shorten this timeline, the Medicines Evaluation Board (MEB) and the Care Institute Netherlands (ZIN), two key bodies involved in the Dutch market access procedure, launched a pilot which introduces a redesigned…

Continue reading on website
Other news

Year in Review: Helping Companies Get Back to Growth

January 19, 2023
Over the past twelve months at Simon-Kucher, our global team of experts have been advising businesses on how to emerge from the crisis, not just in one piece, but actually positioned to accelerate top-line growth. CEOs Mark Billige and Andreas von der Gathen reflect on the creative solutions and strategies that enabled companies to shape their own success and discuss three mega trends dominating t

Seven Design Decisions to Consider when Developing B2B Dynamic Pricing Engines

January 19, 2023
*//*-->*//*-->*//*-->*//*-->*//*-->*/In our previous article we provided a general introduction on ML-based B2B dynamic pricing and its benefits. Now, in Part 2 expert Kiran Pudi answers some common and crucial questions that surface when designing a model.There are several key design choices and decisions that need to be made when developing a dynamic pricing engine. These decisions have implicat